Bausch + Lomb confirms its organic growth

Due to strong sales in the second quarter, including better-than-expected organic growth at Bausch + Lomb, Bausch Health raised its adjusted Ebitda guidance for the full financial year. The Canadian group - previously called Valeant Pharmaceuticals - now expects it to be in the range of $3,200 to $3,350 million, ...

To continue reading this article subscribe now

Already an Eyewear Intelligence subscriber? Sign in here.


Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

To continue reading this article register now.